CAPTRUST Financial Advisors
CTKB icon

CAPTRUST Financial Advisors’s Cytek Biosciences CTKB Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$71.8K Buy
16,434
+2,387
+17% +$11.3K ﹤0.01% 2855
2025
Q4 		$70.9K Sell
14,047
-1,231
-8% -$5.72K ﹤0.01% 2645
2025
Q3 		$53K Buy
15,278
+2,574
+20% +$9.66K ﹤0.01% 2557
2025
Q2 		$43.2K Buy
+12,704
New +$42.3K ﹤0.01% 2439
2022
Q3 		– Sell
-338
Closed -$4K – 2495
2022
Q2 		$4K Sell
338
-26
-7% -$259 ﹤0.01% 4172
2022
Q1 		$4K Buy
+364
New +$4.92K ﹤0.01% 4238

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAPTRUST Financial Advisors's CTKB Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Cytek Biosciences (CTKB) stake by 17% in Q1 2026, buying an estimated $11.3K and bringing the position to 16,434 shares worth $71.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2855.

CAPTRUST Financial Advisors first reported a position in CTKB in Q1 2022 and has held it in 6 quarters since. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • CAPTRUST Financial Advisors held 16,434 shares of Cytek Biosciences worth $71.8K as of Q1 2026.
  • CAPTRUST Financial Advisors bought 2,387 Cytek Biosciences shares in Q1 2026, an estimated $11.3K.
  • Cytek Biosciences made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #2855 holding.
  • CAPTRUST Financial Advisors first reported a position in Cytek Biosciences in Q1 2022 and has held it in 6 quarters since.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.